This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Head and neck cancer	CXC chemokine receptor 7 (CXCR7)	Mouse studies suggest CXCR7-targeting nanobodies could help treat head and neck cancers. In a xenograft mouse model of $CXCR7^+$ human head and neck squamous cell carcinoma, injection of a CXCR7-targeting nanobody decreased tumor growth compared with saline injection. Next steps could include evaluating the CXCR7-targeting nanobody in additional head and neck cancer models. Ablynx N.V. collaborated on the study and has multiple nanobodies in clinical and preclinical development for various diseases. The company has not disclosed if there is a CXCR7-targeting nanobody in its pipeline. ChemoCentryx Inc.'s CCX650, a small molecule CXCR7 antagonist, is in preclinical development to treat brain cancer. *SciBX* 6(37); doi:10.1038/scibx.2013.1027 Published online Sept. 26, 2013	Patent and licensing status unavailable	Maussang, D. *et al. J. Biol. Chem.*; published online Aug. 26, 2013; doi:10.1074/jbc.M113.498436 **Contact:** Martine J. Smit, Free University Amsterdam, Amsterdam, the Netherlands e-mail: mj.smit@vu.nl